申请人:——
公开号:US20040058923A1
公开(公告)日:2004-03-25
Compounds of formula (I) wherein: R
1
represents C
1-16
alkyl, C
2-6
alkenyl, C
2-6
alkynyl, C
2-6
alkynyl-Y
1
—, aryl-Y
1
—, heteroaryl-Y
1
—, aryl-(O)
t
-aryl-Y
1
—, aryl-(O)
t
-heteroaryl-Y
1
—, heteroaryl-(O)
t
-aryl-Y
1
—, heteroaryl-(O)
t
-heteroaryl-Y
1
—, C
2-6
alkenyl-Y
1
—, aryl-O—Y
1
—, heteroaryl-O—Y
1
—, C
1-16
alkyl-SO
2
—Y
1
—,M—Y
1
—,J
2
-Y
1
—, —CN or C
3-8
cycloalkyl-Y
1
— or C
3-8
cycloalkenyl-Y
1
—, which cycloalkyl or cycloalkenyl may be optionally substituted by one or more hydroxyl or C
1-16
Alkyl groups; R
2
represents hydrogen or C
1-16
alkyl; X represents ethylene or a group of formula CR
e
R
f
wherein R
e
and R
f
independently represent hydrogen or C
1-14
alkyl or R
e
and R
f
may together with the carbon atom to which they are attached form a C
3-8
cycloalkyl group; R
3
and R
4
independently represent hydrogen or C
1-14
alkyl; Z represents a bond, CO, SO
2
, CR
9
R
6
(CH
2
)
n
, (CH
2
)
n
CR
9
R
6
, CHR
6
(CH
2
)
n
O, CHR
6
(CH
2
)
n
S, CHR
6
(CH
2
)
n
OCO, CHR
6
(CH
2
)
n
CO, COCHR
6
(CH
2
)
n
or SO
2
CHR
6
(CH
2
)
n
; n represents an integer from 0 to 4; processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.
1
式(I)的化合物,其中:R1代表C1-16烷基,C2-6烯基,C2-6炔基,C2-6炔基-Y1—,芳基-Y1—,杂环芳基-Y1—,芳基-(O)t-芳基-Y1—,芳基-(O)t-杂环芳基-Y1—,杂环芳基-(O)t-芳基-Y1—,杂环芳基-(O)t-杂环芳基-Y1—,C2-6烯基-Y1—,芳基-O—Y1—,杂环芳基-O—Y1—,C1-16烷基-SO2—Y1—,M—Y1—,J2-Y1—,—CN或C3-8环烷基-Y1—或C3-8环烯基-Y1—,其中环烷基或环烯基可以选择地被一个或多个羟基或C1-16烷基基团取代;R2代表氢或C1-16烷基;X代表乙烯或公式CReRf的基团,其中Re和Rf独立地代表氢或C1-14烷基,或Re和Rf可以与它们连接的碳原子一起形成C3-8环烷基基团;R3和R4独立地代表氢或C1-14烷基;Z代表键,CO,SO2,CR9R6(CH2)n,(CH2)nCR9R6,CHR6(CH2)nO,CHR6(CH2)nS,CHR6(CH2)nOCO,CHR6(CH2)nCO,COCHR6(CH2)n或SO2CHR6(CH2)n;n代表一个从0到4的整数;它们的制备方法,包含它们的配方以及它们在治疗炎症性疾病中的用途。